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Fc Receptors IIa on Cardiomyocytes and Their
Potential Functional Relevance in Dilated Cardiomyopathy
Alexander Staudt, MD,* Petra Eichler, PHD,† Christiane Trimpert, MSC,* Stephan B. Felix, MD,*
Andreas Greinacher, MD†
Greifswald, Germany
Objectives The purpose of this study was to investigate how cardiac autoantibodies might contribute to cardiac dysfunction
in patients suffering from dilated cardiomyopathy (DCM).
Background In the majority of DCM patients, it is possible to detect antibodies with negative inotropic effect on cardiomyo-
cytes. The manner in which these antibodies impair cardiac function is poorly understood.
Methods Immunoglobulin (Ig)G was prepared from plasma of 11 DCM patients containing antibodies that induced a nega-
tive inotropic effect on cardiomyocytes. We analyzed the effects of antibodies/IgG fragments on calcium tran-
sients and on systolic cell shortening of adult rat cardiomyocytes and investigated the dependency of these ef-
fects on potential cardiomyocyte Fc receptors.
Results In contrast to control subjects, intact IgG from DCM patients reduced calcium transients and cell shortening of
cardiomyocytes. The F(ab=)2 fragments of these antibodies did not induce these effects but inhibited the func-
tional effects of DCM-IgG of the respective patients’ IgG. These effects were also inhibited by Fc fragments of
normal IgG. Reconstitution of the Fc part by incubation of cardiomyocytes with DCM-F(ab=)2 fragments followed
by goat-anti-human-F(ab=)-IgG again induced reduction of cell shortening and of calcium transients. In rat and
human ventricular cardiomyocytes, Fc receptors IIa (CD32) were demonstrated by immunofluorescence.
Conclusions Our findings indicate that DCM-IgG-F(ab=)2 bind to their cardiac antigen(s), but the Fc part might trigger the neg-
ative inotropic effects via the newly detected Fc receptor on cardiomyocytes. These results point to a novel po-
tential mechanism for antibody-induced impairment of cardiac function in DCM patients. (J Am Coll Cardiol
2007;49:1684–92) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.051a
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rilated cardiomyopathy (DCM) is a frequently occurring
yocardial disease with poor prognosis that is characterized
y progressive depression of myocardial contractile function
nd by ventricular dilatation (1,2). Disturbances in humoral
mmunity play an important role in the cardiac dysfunction
See page 1693
f DCM patients (3–9). A number of autoantibodies
gainst various cardiac cell proteins have been identified in
CM: for example, antibodies against mitochondrial pro-
eins, contractile proteins, beta-1-receptors, and musca-
inergic receptors (3,10–13). Studies with an animal model
or anti–beta-1-receptor antibodies have especially demon-
trated the biological relevance of these antibodies and their
rom the *Klinik für Innere Medizin B and the †Institut für Immunologie und
ransfusionsmedizin, Ernst-Moritz-Arndt-Universität, Greifswald, Germany. This
tudy was supported in part by a grant from the Deutsche Forschungsgemeinschaft
SFB-TR 19) and by the Department of Cardiovascular Medicine.t
Manuscript received July 20, 2006; revised manuscript received October 13, 2006,
ccepted November 6, 2006.ssociation to DCM (14). Animal models further indicate
hat, under certain pathological conditions, DCM can be
riggered by autoantibodies. BALB/c mice, deficient for the
mmune-regulatory program death receptor-1 (PD-1), gen-
rate autoantibodies against cardiac troponin I. Antibodies
gainst cardiac troponin I bind to the surface of cardiomyo-
ytes, as shown by immunoelectron microscopy. These
utoantibodies induce cardiac dysfunction in animals similar
o that seen in human DCM patients (15,16).
We have recently shown that antibodies from DCM
atients induce an acute negative inotropic effect in isolated
at cardiomyocytes through depression of calcium tran-
ients. Removal of these antibodies from patients’ plasma by
herapeutic immunoadsorption improves cardiac function in
atients with heart failure due to DCM (8). Only those
CM patients in whom a negative inotropic effect of the
ntibodies was documented in vitro experienced clinical
enefit during the following immunoadsorption (9). A
ariety of different epitopes on cardiomyocytes might rep-
esent potential antigens responsible for the induction of
hese functional effects in cardiomyocytes. Whereas each of
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April 24, 2007:1684–92 Fc Receptors on Cardiomyocyteshe 2 Fab fragments of an immunoglobulin (Ig)G antibody
xpresses the hypervariable region that is responsible for
pecificity of the antibody and by which the antibody binds
o its antigen, the Fc part does not differ among antibodies
f the same IgG subclass. The Fc part is important for the
iological effects of IgG, because it interacts with Fc
eceptors that are expressed on many cells (e.g., leukocytes,
ndothelial cells, and platelets). Accordingly, we studied the
ole of the effector part of negative inotropic antibodies. In
his context, we also investigated the existence of Fc
eceptors on cardiomyocytes as well as their potential
unctional relevance. Our findings indicate that Fc
eceptors might play an important pathogenic role in
CM, because cardiac autoantibodies evidently bind
ith their Fab part to structures on the cardiomyocytes
ut then crosslink via their Fc part the Fc receptors on
ardiomyocytes.
ethods
reparation of plasma IgG. Immunoglobulin G was pre-
ared from plasma of 11 DCM patients with antibodies that
nduced a negative inotropic effect on cardiomyocytes, as
escribed earlier (9). The negative inotropic effects were
efined by a reduction of systolic cell shortening (10%)
aused by a decrease of calcium transients (10%) (9). The
CM was diagnosed by standard methods (5). Antibodies
ere purified by an anti-IgG column (PlasmaSelect, Teterow,
ermany), dialyzed (molecular weight cutoff 100 kDa) against
xperimental buffer (117 mmol/l sodium chloride (NaCl),
.8 mmol/l potassium chloride (KCl), 0.6 mmol/l magne-
ium chloride, 1.2 mmol/l potassium phosphate monobasic,
.2 mmol/l potassium dihydrogen phosphate, 20 mmol/l
lucose, and 10 mmol/l HEPES; pH 7.3) for 30 h,
ncubated (56°C, 30 min) for inactivation of complement
8,9), and stored in aliquots at 70°C. Immunoglobulin G
rom healthy blood donors (control subjects) was prepared
dentically.
easurement of intracellular calcium transients and
ystolic cell shortening. The isolation of ventricular car-
iomyocytes from adult Wistar rats and the measurements
f intracellular calcium transients and of systolic cell short-
ning were performed as described earlier (8,9,17). Briefly,
he cardiomyocytes were suspended in experimental buffer
nd stained with the calcium fluorescent probe Fura 2-AM.
ingle cardiomyocytes were field-stimulated (1 Hz, 5 ms)
nd superfused continuously with experimental buffer (2
l/min) containing DCM patient IgG (300 g/ml) or the
espective F(ab=)2 fragments (200 g/ml), control IgG (300
g/ml), and anti-Fab antibodies (30 g/ml). For analysis of
he involvement of the specific binding of the F(ab=)2 part to
ts antigen, we pre-incubated the cardiomyocytes with the
(ab=)2 fragments (56 g/ml) of each of the eleven DCM
atients for 30 min, rinsed with buffer, and superfused the
ardiomyocytes with the intact IgG of the respective pa-
ient. To assess the involvement of the Fc part in the aunctional effects of the autoan-
ibodies, cardiomyocytes were
re-incubated with human Fc
ragments (30 g/ml).
Fluorescence measurements
ere recorded with a dual-
xcitation, single-emission fluo-
escence photomultiplier system (IonOptix, Milton, Mas-
achusetts). Changes in intracellular calcium transients were
nferred from the ratio of the fluorescence intensity at 2
avelengths (9). A video-imaging edge detector system
IonOptix) was used for measurements of cell length, as
escribed elsewhere (9,18). The relative change of calcium
ransients and systolic cell shortening was expressed as the
ean of the experiments, with at least 6 different cardio-
yocytes from 6 different cardiomyocyte preparations per
gG preparation (8,9). At baseline, all measured cardiomy-
cytes showed systolic cell shortening of more than 8%
mean 11.3  0.5%). The experiments were performed in
linded fashion. In all experiments, antibodies with (posi-
ive control) and without (negative control) functional
ctivity were additionally tested on the same cardiomyocyte
reparation. Each aliquot of cardiomyocytes was used only
or a single investigation of the one Ig sample.
To determine whether the functional effects are mediated
y the F(ab=)2 part of the antibodies, F(ab=)2 fragments were
repared (pepsin digestion) and purified (fast performance
iquid chromatography) from patient IgG and control IgG
y the Biotech Company Biogenes (Berlin, Germany). The
gG and the respective F(ab=)2 fragments from each patient
ere used in equimolar concentrations. For assessment of
he involvement of the Fc part of antibodies in the func-
ional effects, Fc fragments of normal IgG were used (kindly
rovided by Behringwerke, Marburg, Germany). For recon-
titution of the Fc parts of the IgG-F(ab=)2 fragments,
ardiomyocytes were pre-incubated with the F(ab=)2 frag-
ents of DCM patients (56 g/ml; 30 min), rinsed, and
uperfused with goat-anti-human-F(ab=) IgG (Sigma-
ldrich Chemie, Taufkirchen, Germany) (30 g/ml).
solation of human cardiomyocytes from endomyocardial
iopsies. Isolation of human cardiomyocytes was per-
ormed as described elsewhere (19). From DCM patients
n  8) we obtained 8 to 10 endomyocardial biopsies from
he interventricular septum of the right ventricle (7). Briefly,
part of the endomyocardial biopsies was transported
mmediately to the laboratory for cell isolation within 5 min,
n ice-cold HEPES-buffered salt solution (pH  7.0)
ontaining the following: 120 mmol/l NaCl, 5.4 mmol/l
Cl, 0.5 mmol/l magnesium sulfate, 5.0 mmol/l sodium
yruvate, 20 mmol/l glucose, 10 mmol/l HEPES, and 6
mol/l nitrilotriacetic acid (Sigma-Aldrich Chemie). The
iopsies were placed in a 2-ml tube in a water bath (35°C)
or enzymatic digestion. The continuously gassed digestion
edia consist of the HEPES-buffered solution with a
alcium concentration of 50 mol/l and 1% bovine serum
Abbreviations
and Acronyms
DCM  dilated
cardiomyopathy
Ig  immunoglobulinlbumin. In the first step the biopsies were incubated with
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Fc Receptors on Cardiomyocytes April 24, 2007:1684–92rotease type XXIV (4 U/ml) (Sigma-Aldrich Chemie) for
5 min. The biopsies were replaced in a fresh tube contain-
ng buffer with a combination of 1 mg/ml collagenase-A
Worthington, Lakewood, New Jersey) and 0.5 mg/ml
yaluronidase (Sigma-Aldrich Chemie). After 20 min the
ells were centrifuged (4 min, 240 g), and the supernatant
as replaced by a fresh pure collagenase-A solution for
dditional 20-min incubation. To terminate the digestion
rocess, the cell pellet was washed once in the media
ithout enzyme. Finally, the cell pellet was resuspended in
.5 ml phosphate buffered saline (PBS) buffer and passed
hrough a filter to remove undigested tissue.
Written consent was obtained from each patient, and the
rotocol was approved by the Ethics Committee of the
niversity Hospital of Greifswald.
ndirect immunofluorescence. Isolated cardiomyocytes
ere allowed to adhere on cover slips (1 h, 37°C); fixed with
araformaldehyde (2% in PBS, 10 min, room temperature,
ithout additional permeabilization); blocked with PBS
ontaining 3% bovine serum albumin/0.05% Tween20 for
5 min; and stained with polyclonal goat antibodies against
c receptor I (CD 64), Fc receptor II (CD 32), Fc
eceptor IIa, Fc receptor IIb, Fc receptor IIb/c, and Fc
eceptor III (CD 16) (4 g/ml, 2 h, room temperature).
oat IgG was used as negative control, and a polyclonal
oat antibody against troponin I served as positive control.
urthermore, rat leukocytes were employed as an additional
ositive control for detection of Fc receptors IIa to dem-
nstrate that the antibody, which recognizes human Fc
eceptors IIa, also reacts with the rat Fc receptors IIa.
uman fibroblasts served as additional negative control. For
etection, cells were incubated with rhodamine-conjugated
ovine anti-goat IgG antibodies (30 min, room tempera-
ure, 1:400). The cellular nuclei were stained with DAPI
4’,6-Diamidino-2-phenyindole, dilactate) (Sigma-Aldrich
hemie) (1 g/ml in PBS) for 2 min. Before immunoflu-
rescence analysis of a high-power microscopic field, the
dentity of cells was additionally verified by light
icroscopy.
Isolated human cardiomyocytes were treated according to
he same immunofluorescence protocol as rat cardiomyo-
ytes but with antibody treatment carried out in solution.
ll primary and secondary antibodies were purchased from
anta Cruz Biotechnology (Heidelberg, Germany). Cover
lips were mounted on slides with GelMount (Sigma-
ldrich Chemie) and examined with a fluorescence micro-
cope (Leica DMLB, Benzheim, Germany). A constant
xposure time of 10 s was used for rhodamin-conjugated
ntibodies, and 50 ms was used for DAPI staining.
tatistics. Results are expressed as mean  SEM. The
nalyses included comparisons between the groups (con-
rol subjects vs. DCM) and within the groups. Analyses
ere performed by Mann-Whitney U tests and Wilcoxon
igned rank tests. Significance was assessed at the p 
.05 level.esults
ffects of intact IgG and F(ab=)2 fragments of DCM
atients. The intact IgG fractions (300 g/ml) of plasma
rom 11 DCM patients with negative inotropic antibodies
mean age  46  3 years; 10 male/1 female patient;
jection fraction 30%, New York Heart Association func-
ional class III to IV) immediately reduced calcium tran-
ients by 14  1% and systolic cell shortening of rat
ardiomyocytes by 19  1% (p  0.001 vs. control IgG).
ontrol IgG had no effect (Fig. 1A). The F(ab=)2 fragments
f patient IgG and control subjects showed no functional
Figure 1 Effects of Intact IgG/Antibody Fragments
on Isolated, Field-Stimulated Rat Cardiomyocytes
Changes of calcium transients and systolic cell shortening during superfu-
sion (% changes from baseline; mean  SEM; n  6 experiments for each
patient’s/control sample) with: intact immunoglobulin (Ig)G from plasma of
healthy blood donors (control IgG) and intact IgG from dilated cardiomyopathy
(DCM) patients (DCM-IgG); F(ab=)2 fragments of control IgG and of respective
DCM-IgG; intact DCM-IgG after pre-incubation with the F(ab=)2 fragments of con-
trol subjects and of respective DCM patients; intact DCM-IgG after pre-incuba-
tion of cardiomyocytes with human Fc fragments; and goat-anti-human-F(ab=)-
IgG after pre-incubation of cardiomyocytes with F(ab=)2 fragments of control IgG
and of respective DCM patients. p  0.001 significantly different from
control IgG; ***p  0.001 significantly different from DCM-IgG.
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April 24, 2007:1684–92 Fc Receptors on Cardiomyocytesffects (p  0.001 vs. DCM IgG), which indicates that
inding of F(ab=)2 fragments to its antigen alone is not
ufficient to induce negative inotropic effects (Fig. 1B).
When we pre-incubated cardiomyocytes with the F(ab=)2
ragments (56 g/ml) of each of the 11 DCM patients for
0 min, rinsed with buffer, and superfused the cardiomyo-
ytes with the intact IgG of the respective patient, the
(ab=)2 fragments blocked the negative inotropic effect of
he intact patient’s IgG (p  0.001 vs. DCM IgG) (Fig.
B). The F(ab=)2 fragments of control IgG (n  6), in
ontrast, did not inhibit the effects of intact IgG of DCM
atients (Fig. 1B). This indicates that the DCM F(ab=)2
ragments inhibit binding of intact antibodies to their
espective antigen: a process evidently crucial for inducing
he observed functional effects of DCM IgG on cardiomy-
cytes (Fig. 2).
To assess whether the antibodies in different DCM
atients bind to the same or to different antigen-binding
ites, cardiomyocytes were pre-incubated with F(ab=)2 frag-
ents of 1 patient, rinsed, and then superfused with the
gG antibodies of another patient. Three different patients’
(ab=)2 fragments were tested in this way against antibodies
f 3 other DCM patients. As an indication for the involve-
ent of different cardiac antigens in 8 of 9 blocking
xperiments, the DCM F(ab=)2 fragments did not inhibit
Figure 2 Summary of Functional Findings
Intact immunoglobulin (Ig)G of dilated cardiomyopathy (DCM) patients induced neg
myocytes and then via their Fc part to the Fc receptor IIa (FcR) (A). The F(ab=)2 f
ments of normal IgG (C). Reconstitution of Fc parts by sequential incubation of ca
negative inotropic effect (D) comparable to findings for intact DCM IgG. A detailedhe effects of functionally active, intact antibodies from
ther DCM patients (data not shown).
ole of the Fc part of the antibodies in the functional
ffects. The F(ab=)2 fragments lack the Fc part of intact
gG. In contrast to the specific antigen binding sequence of
he F(ab=)2 part, the Fc parts of various antibodies of the
ame IgG subclass do not differ in their structure. To assess
he involvement of the Fc part in the functional effects of
he autoantibodies, we pre-incubated cardiomyocytes with
uman Fc fragments (30 g/ml) for 30 min, rinsed, and
uperfused the cardiomyocytes with the IgG antibodies of a
CM patient (n  6), and analyzed the inotropic effects.
hereas Fc fragments alone demonstrated no effect (data
ot shown), pre-incubation of cardiomyocytes with Fc
ragments of normal IgG completely inhibited the func-
ional effects of intact DCM IgG (p 0.001 vs. DCM IgG)
Fig. 1C).
To verify that both the Fab part of DCM IgG and the Fc
art are required for the functional effects of the antibodies,
e reconstituted the Fc part of the F(ab=)2 fragments of
CM IgG antibodies by sequential incubation of rat
ardiomyocytes with the F(ab=)2 fragments of DCM IgG,
ollowed by an intact goat-anti-human-F(ab=) IgG. This
esulted again in reduction of systolic cell shortening
20  2%) and of calcium transients (14  2%)
notropic effects by binding via their Fab part to the antigenic epitope on cardio-
nts of these antibodies inhibited the effect of intact DCM IgG (B), as did Fc frag-
ocytes with DCM F(ab=)2 fragments and goat-anti-human F(ab=) IgG induced a
iption of Fc receptor cross linking is in the Discussion section. AG  antigen.ative i
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Fc Receptors on Cardiomyocytes April 24, 2007:1684–92omparable to intact DCM patient IgG (p  0.001 vs.
ontrol IgG) (Fig. 1C). Sequential incubation of cardiomy-
cytes with F(ab=)2 fragments of control IgG and goat-anti-
uman-F(ab=) IgG demonstrated no functional effects (Fig.
C). This is further evidence that DCM IgG induces
unctional effects on cardiomyocytes only if it can bind with
ts Fab part and its Fc part to cardiomyocytes (Fig. 2). This
iew of a potential mechanism is supported by the fact that,
fter removal of immune complexes by ultracentrifugation,
he negative inotropic effects of intact DCM patient IgG
emain detectable. Potential direct anti-Fc receptor-IIa
ctivity of DCM IgG was excluded by an established system
sing platelets (20). Preincubation of platelets with DCM
era (n  6) did not cause platelet activation; nor did it
nhibit platelet activation by sera (n  2) of patients with
eparin-induced thrombocytopenia that still activated
latelets via the Fc receptor IIa.
etection of Fc receptors on rat and human cardio-
yocytes. Binding of the IgG Fc part to cells occurs via
c receptors. By immunofluorescence we detected Fc
eceptors II (CD32) on rat cardiomyocytes (Fig. 3), which
tained positive with anti-Fc receptor-IIa antibodies but
ot with anti-Fc receptor IIb, anti-Fc receptor IIb/anti-
c receptor IIc, anti-Fc receptor III, or anti-Fc receptor
antibodies (Figs. 3 and 4). Human cardiomyocytes isolated
Figure 3 Fc Receptor on Rat Cardiomyocytes
Immunofluorescent staining of isolated rat cardiomyocytes with a rhodamine-conju
mary antibodies against Fc receptor I (CD64), Fc receptor II (CD32), or Fc recep
negative and positive control subjects, respectively (counterstaining with 4’,6-Diam
each antibody).rom endomyocardial biopsies of DCM patients (n  8)
lso stained positive for the Fc receptor IIa but not for Fc
eceptor IIb or Fc receptor IIc (Fig. 5). However, it cannot
e excluded that the other Fc receptors are expressed below
he detection limit of the immunofluorescence method
mployed. Goat-normal IgG and human fibroblasts served
s negative control subjects. Antibodies against troponin I
nd rat leukocytes served as positive control subjects (Figs.
, 4, and 5). Counterstaining with DAPI demonstrates that
he positive immunofluorescence staining is located on
ardiomyocytes. However, in negative control subjects (goat
gG) the cardiomyocytes produced no positive immunoflu-
rescence staining (Fig. 4). In all immunofluorescence
xperiments, the majority of the cells (90%) displayed the
ypical staining as shown in the figures.
The polyclonal anti-Fc receptor II antibody (8 g/ml)
lone induced negative inotropic effects (cell shortening:
18.1  3% and calcium transient: 11.3  2%); anti-Fc
eceptor IIa antibodies induced a moderate cardiodepressant
ffect (cell shortening: 11.4  2% and calcium transient:
7.9  1%). For this reason, we did not perform preincu-
ation of cardiomyocytes with these antibodies for inhibi-
ion of the functional effects induced by DCM IgG.
reincubation of cardiomyocytes with a tyrosine kinase
locker (PP2 [4-Amino-5-(4-chlorophenyl)-7-(t-butyl)
bovine anti-goat secondary antibody after pre-incubation with polyclonal goat pri-
(CD16); goat immunoglobulin (Ig)G and antibodies against troponin I, serving as
-phenyindole, dilactate [DAPI]; representative figures of n  6 experiments forgated
tor III
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April 24, 2007:1684–92 Fc Receptors on Cardiomyocytesyrazolo[3,4-d]pyrimidine], 1 mol/l)—a crucial enzyme of
he signal cascade of Fc receptor IIa—blocked the effects
f intact DCM IgG (cell shortening: 1.3  1% and
alcium transient: 0.9  1%).
iscussion
ardiac Fc receptors IIa and their potential functional
elevance. Disturbances of the humoral immune system
lay an important role in the pathogenesis of DCM. The
resent study suggests that DCM IgGs, although binding
o their respective cardiac epitopes via their Fab parts,
nduce their negative inotropic effects via their Fc part by
inding to the newly detected Fc receptor IIa on cardio-
yocytes. The Fc receptors IIa can induce an activating
ignal via its cytoplasmic domains, thereby possibly trigger-
ng the negative inotropic effect. The proposed model of Fc
eceptor-dependent activation of cardiomyocytes by DCM
utoantibodies provides an explanation of why antibodies
irected against different antigens on cardiomyocytes can
nduce the same functional effects. However, we can merely
peculate about the potential role of the interaction between
ntibodies and the Fc receptor on the pathogenesis of
Figure 4 Fc Receptor Type IIa on Rat Cardiomyocytes
Immunofluorescent staining of isolated rat cardiomyocytes with a rhodamine-conju
mary antibodies against Fc receptor IIa, Fc receptor IIb, or Fc receptor IIb/c. Im
anti-goat secondary antibody after preincubation with polyclonal goat primary antib
tively (counterstaining with 4’,6-Diamidino-2-phenyindole, dilactate [DAPI]; represenCM. iFigure 2 summarizes our major findings: whereas intact
gG of DCM patients induced negative inotropic effects
Fig. 2A), their respective F(ab=)2 fragments did not. How-
ver, these F(ab=)2 fragments inhibited the effect of intact
CM IgG (Fig. 2B), as did Fc fragments of normal IgG
Fig 2C). When we reconstituted the Fc part of the
uman-DCM-F(ab=)2 fragments by adding an anti-human-
(ab=) antibody, the resulting “extra-long” IgG molecule
nduced a pronounced negative inotropic effect comparable to
ndings for intact DCM IgG (Fig. 2D). Interestingly, we
bserved in previous studies that DCM antibodies of the
gG-3 subclass, which are the longest IgG molecules, play
n important role in the negative inotropic effects of DCM
ntibodies on cardiomyocytes in vitro (21). In accordance
ith these in vitro experiments, we were able to measure the
mprovement in cardiac function of DCM patients during
mmunoadsorption therapy only if antibodies belonging to
he IgG-3 subclass were also effectively depleted—but not if
gG-1, IgG-2, and IgG-4 antibodies alone were removed
rom patient plasma (21,22). This might indicate that the
c part of IgG-3 has enhanced affinity for the involved Fc
eceptor, as is the case for the Fc receptor IIa (23), or it
ight indicate a large spatial distance between the antigens
bovine anti-goat secondary antibody after preincubation with polyclonal goat pri-
uorescence of fibroblasts and rat leukocytes with a rhodamine-conjugated bovine
against Fc receptor IIa served as negative and positive control subjects, respec-
figures of n  6 experiments for each antibody).gated
munofl
odies
tativenvolved in DCM and the Fc receptor that could be
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Fc Receptors on Cardiomyocytes April 24, 2007:1684–92ridged only by the longer Fc part of IgG-3. Biologically,
his might represent a protection mechanism that prevents
ll antibodies against cardiomyocytes from inducing Fc
eceptor-dependent cell activation, with potential, conse-
uent, severe cell damage. The DCM antibodies do not
ind with their Fab part to the Fc receptor but to other
ntigens on the cardiomyocyte. We assume that the anti-
en(s) allows binding of several antibodies in close proxim-
ty to each other: these clustered antibodies then crosslink
he Fc receptor IIa via their Fc-part, thereby causing
lustering and activation. As in other cells, Fc receptors IIa
equire clustering before they are activated; this might also
e the case for activation of Fc receptor IIa in cardiomy-
cytes. Monomeric IgG or Fc parts that do not perform
rosslinking can inhibit this activation (24). Furthermore, as
n other cells, it is possible that a polymorphism of cardiac
c receptor IIa might influence the response of the
eceptor (25). However, this point should be elucidated in a
arger study population.
ole of the IgG Fab. In our study, F(ab=)2 fragments of
particular patient did not block the effects of the IgG of
ther DCM patients. This finding strongly indicates that
ifferent antibody binding sites are involved in different
atients. We cannot differentiate whether these antigens
re exposed on the same protein or on different proteins.
Figure 5 Fc Receptor Type IIa on Human Cardiomyocytes
Immunofluorescent staining of human cardiomyocytes isolated from endomyocardi
incubation with polyclonal goat primary antibodies against Fc receptor IIa, Fc rec
serving as negative and positive control subjects, respectively (representative figurfter binding of the DCM IgG to their respective sntigens via the Fab part, their Fc parts bind to Fc
eceptors (Fig. 2).
Although the F(ab=)2 fragments we assessed had no
hort-term functional activity, some DCM autoantibodies
ight very well also induce specific effects caused by binding
o their epitope via the Fab part alone. This might be the
ase for antibodies directed against the beta-1-receptor,
hich induce a positive inotropic effect and an increase of
yclic adenosine monophosphate in cardiomyocytes (26,27)
r for antibodies directed against cardiac troponin I, which
nduce enhancement of calcium current in cardiomyocytes
16). However, because all these experiments were per-
ormed with total IgG antibodies, the role of the Fc part of
hese antibodies remains to be elucidated. In our experi-
ents, effects induced by cross-linking of the antigen on
ardiomyocytes are unlikely, because the F(ab=)2 fragments
f the antibodies had no functional effects on cardiomyo-
ytes, although they should logically be able to crosslink the
roteins to which they bind as effectively, as does total IgG
Fig. 1). We also addressed the issue of inhibitory anti-
diotype antibodies by our experiments. Anti-idiotype
(ab=)2 fragments would be able to inhibit DCM idiotype
ntibodies and could be an explanation for the inhibitory
ffect of F(ab=)2 fragments. However, in our experiments,
he F(ab=)2 fragments and the DCM IgG were incubated
sies with a rhodamine-conjugated bovine anti-goat secondary antibody after pre-
Ib, or Fc receptor IIc; goat immunoglobulin G and antibodies against troponin I,
n  6 experiments for each antibody).al biop
eptor I
es ofequentially (not at the same time; i.e., we first incubated
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April 24, 2007:1684–92 Fc Receptors on Cardiomyocytesith F(ab=)2, washed the cells, and then incubated with
ntact DCM IgG). It is therefore highly unlikely that
nti-idiotype antibodies are the reason for the inhibitory
ffect of some F(ab=)2 fragments.
A recent study disclosed that intact IgG (but not F(ab=)2
ragments) markedly ameliorates experimental giant cell
yocarditis (28). The authors primarily explained this effect
y suppression of dendritic cells. Furthermore, Gullestad et
l. (29) suggested that IgG treatment might induce benefi-
ial effects in patients with heart failure. On the basis of the
resent study, some of the effects might have been induced
y functional blockade of cardiac Fc receptors by high-dose
gG.
Our experiments imply that IgG binding to cardiomyo-
yte surface antigens as well as Fc receptors IIa accom-
lishes cross-linking of the Fc receptors IIa and thereby
nitiates signaling. This binding initiates a process that
nhibits acute cardiomyocyte contractility by suppression of
alcium transients. In hematopoietic cells, activation of Fc
eceptor IIa induces an increase of intracellular calcium
evels via tyrosine kinase pathways (30,31). Inhibition of the
ardiosuppressant effects of DCM antibodies by the tyrosin
inase inhibitor PP2 provides further evidence for an
mportant role of Fc receptors IIa in DCM.
The present study has parallel implications with respect
o another severe immune-mediated disorder in cardiovas-
ular medicine: heparin-induced thrombocytopenia (32). In
eparin-induced thrombocytopenia, antibodies are gener-
ted against the self-protein, platelet factor 4, when platelet
actor 4 forms multimolecular complexes with heparin (33).
his results in immune complexes, which activate platelets
y cross-linking their Fc receptors IIa (20). Intravascular
ctivation of platelets results in enhanced thrombin gener-
tion and can lead to catastrophic thromboembolic compli-
ations (34). We hypothesize that a similar mechanism is
asically involved in DCM (i.e., autoantibodies bind to their
ntigen via the Fab part and then induce cardiac dysfunction
y activating Fc receptors IIa on cardiomyocytes). This
odel might also be potentially applied for other antibody-
ediated degenerative autoimmune disorders.
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